Chk1/2 inhibitors in combination with IR increased micronuclei formation (potentially increasing cGAS–STING activation) and type I IFNβ production in vitro and demonstrated improved immune-mediated tumor control in B16F10 melanoma models [80]. This evidence concerns the gene STING1 and neoplasm.